| Year |
Citation |
Score |
| 2024 |
Harris BHL, Di Giovannantonio M, Zhang P, Harris DA, Lord SR, Allen NE, Maughan TS, Bryant RJ, Harris AL, Bond GL, Buffa FM. New role of fat-free mass in cancer risk linked with genetic predisposition. Scientific Reports. 14: 7270. PMID 38538606 DOI: 10.1038/s41598-024-54291-7 |
0.374 |
|
| 2023 |
Clift AK, Collins GS, Lord S, Petrou S, Dodwell D, Brady M, Hippisley-Cox J. Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study. The Lancet. Digital Health. 5: e571-e581. PMID 37625895 DOI: 10.1016/S2589-7500(23)00113-9 |
0.34 |
|
| 2023 |
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, et al. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4741. PMID 37550302 DOI: 10.1038/s41467-023-40561-x |
0.333 |
|
| 2023 |
Charles Coombes R, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4444. PMID 37488191 DOI: 10.1038/s41467-023-40061-y |
0.309 |
|
| 2023 |
Carroll TM, Chadwick JA, Owen RP, White MJ, Kaplinsky J, Peneva I, Frangou A, Xie PF, Chang J, Roth A, Amess B, James SA, Rei M, Fuchs HS, McCann KJ, ... ... Lord SR, et al. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma. Cancer Cell. 41: 1222-1241.e7. PMID 37433281 DOI: 10.1016/j.ccell.2023.06.006 |
0.328 |
|
| 2023 |
Clift AK, Dodwell D, Lord S, Petrou S, Brady M, Collins GS, Hippisley-Cox J. Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study. Bmj (Clinical Research Ed.). 381: e073800. PMID 37164379 DOI: 10.1136/bmj-2022-073800 |
0.311 |
|
| 2023 |
Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British Journal of Cancer. PMID 36823364 DOI: 10.1038/s41416-023-02204-2 |
0.481 |
|
| 2022 |
Skolariki A, D'Costa J, Little M, Lord S. Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of Targeted Anti-Tumor Therapy. 3: 172-199. PMID 36046843 DOI: 10.37349/etat.2022.00078 |
0.42 |
|
| 2022 |
Harris BHL, Macaulay VM, Harris DA, Klenerman P, Karpe F, Lord SR, Harris AL, Buffa FM. Obesity: a perfect storm for carcinogenesis. Cancer Metastasis Reviews. PMID 36038791 DOI: 10.1007/s10555-022-10046-2 |
0.579 |
|
| 2022 |
Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, Tutt A, Abramson V, Dean E, Haddad TC, Wesolowski R, Ferrer-Playan J, Goddemeier T, Grombacher T, Dong J, et al. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Npj Breast Cancer. 8: 45. PMID 35393425 DOI: 10.1038/s41523-022-00406-0 |
0.331 |
|
| 2022 |
Clift AK, Hippisley-Cox J, Dodwell D, Lord S, Brady M, Petrou S, Collins GS. Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study. Bmj Open. 12: e050828. PMID 35351695 DOI: 10.1136/bmjopen-2021-050828 |
0.305 |
|
| 2021 |
Scott NP, Teoh EJ, Flight H, Jones BE, Niederer J, Mustata L, MacLean GM, Roy PG, Remoundos DD, Snell C, Liu C, Gleeson FV, Harris AL, Lord SR, McGowan DR. Characterising F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. British Journal of Cancer. PMID 34795409 DOI: 10.1038/s41416-021-01623-3 |
0.7 |
|
| 2021 |
Howell S, Krebs M, Lord S, Kenny L, Bahl A, Clack G, Ainscow E, Arkenau H, Mansi J, Palmieri C, Richards P, Jeselsohn R, Mitri Z, Gradishar W, Sardesai S, et al. 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) Annals of Oncology. 32: S477-S478. DOI: 10.1016/j.annonc.2021.08.548 |
0.303 |
|
| 2020 |
Baird RD, Linossi C, Middleton M, Lord S, Harris A, Rodón J, Zitt C, Fiedler U, Dawson KM, Leupin N, Stumpp MT, Harstrick A, Azaro A, Fischer S, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000596. PMID 33301375 DOI: 10.1200/JCO.20.00596 |
0.409 |
|
| 2020 |
Di Giovannantonio M, Harris BH, Zhang P, Kitchen-Smith I, Xiong L, Sahgal N, Stracquadanio G, Wallace M, Blagden S, Lord S, Harris D, Harris AHL, Buffa FM, Bond GL. Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. Journal of Medical Genetics. PMID 32591342 DOI: 10.1136/Jmedgenet-2019-106799 |
0.558 |
|
| 2020 |
Aroldi F, Lord SR. Window of opportunity clinical trial designs to study cancer metabolism. British Journal of Cancer. 122: 45-51. PMID 31819180 DOI: 10.1038/s41416-019-0621-4 |
0.378 |
|
| 2019 |
Lord SR, Collins JM, Cheng WC, Haider S, Wigfield S, Gaude E, Fielding BA, Pinnick KE, Harjes U, Segaran A, Jha P, Hoefler G, Pollak MN, Thompson AM, Roy PG, et al. Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer. PMID 31819193 DOI: 10.1038/s41416-019-0665-5 |
0.763 |
|
| 2019 |
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. The Lancet. Oncology. PMID 31257177 DOI: 10.1016/S1470-2045(19)30328-6 |
0.311 |
|
| 2019 |
Morotti M, Bridges E, Valli A, Choudhry H, Sheldon H, Wigfield S, Gray N, Zois CE, Grimm F, Jones D, Teoh EJ, Cheng WC, Lord S, Anastasiou D, Haider S, et al. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 31152137 DOI: 10.1073/Pnas.1818521116 |
0.671 |
|
| 2018 |
Lord SR, Cheng WC, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson F, Bradley K, Wigfield S, Zois C, McGowan DR, Ah-See ML, Thompson AM, et al. Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism. PMID 30244975 DOI: 10.1016/J.Cmet.2018.08.021 |
0.739 |
|
| 2018 |
Saura C, Thistlethwaite F, Banerji U, Lord S, Moreno V, MacPherson I, Boni V, Rolfo CD, de Vries EG, Van Herpen CM, Rottey S, Geenen JJ, Eskens F, Gil Martin M, Mommers E, et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. Journal of Clinical Oncology. 36: 1014-1014. DOI: 10.1200/JCO.2018.36.15_SUPPL.1014 |
0.364 |
|
| 2017 |
Morotti M, Dass PH, Harris AL, Lord S. Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. European Journal of Drug Metabolism and Pharmacokinetics. PMID 29019020 DOI: 10.1007/s13318-017-0442-x |
0.748 |
|
| 2017 |
Telli M, Lord S, Dean E, Abramson V, Arkenau H, Becerra C, Tolaney S, Tang R, Penney M, Pollard J, Conboy G, Fields S, Shapiro G. Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792) Annals of Oncology. 28: v76. DOI: 10.1093/ANNONC/MDX365.005 |
0.331 |
|
| 2016 |
Mehta S, Hughes NP, Li S, Jubb A, Adams R, Lord S, Koumakis L, van Stiphout R, Padhani A, Makris A, Buffa FM, Harris AL. Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. Ebiomedicine. PMID 27474395 DOI: 10.1016/j.ebiom.2016.07.017 |
0.753 |
|
| 2016 |
Lord S, Funes JM, Harris AL, Quintela-Fandino M. Antiangiogenic resistance and cancer metabolism: opportunities for synthetic lethality. Current Drug Targets. PMID 26953245 DOI: 10.2174/1389450117666160307143718 |
0.54 |
|
| 2016 |
Lord S, Liu D, Cheng W, Haider S, Gaude E, Teoh E, Patel N, Metcalf T, McGowan D, Roxanis I, Qifeng Z, Roy P, Gleeson F, Thompson A, Pollak M, et al. Metformin increases 18F-FDG flux and inhibits fatty acid oxidation at clinical doses in breast cancer: Results of a phase 0 clinical trial European Journal of Surgical Oncology (Ejso). 42: S230. DOI: 10.1016/J.Ejso.2016.07.060 |
0.636 |
|
| 2015 |
Lord SR, Patel N, Liu D, Fenwick J, Gleeson F, Buffa F, Harris AL. Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism. Journal of the National Cancer Institute. Monographs. 2015: 81-6. PMID 26063894 DOI: 10.1093/jncimonographs/lgv011 |
0.535 |
|
| 2015 |
Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, Domarkas J, Lord S, Baldry C, Gilbert FJ. Imaging tumour hypoxia with positron emission tomography. British Journal of Cancer. 112: 238-50. PMID 25514380 DOI: 10.1038/bjc.2014.610 |
0.4 |
|
| 2014 |
Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li JL, Zhang Q, Wakelam MJ, Karpe F, Schulze A, Harris AL. Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Reports. 9: 349-65. PMID 25263561 DOI: 10.1016/j.celrep.2014.08.056 |
0.696 |
|
| 2011 |
Favaro E, Lord S, Harris AL, Buffa FM. Gene expression and hypoxia in breast cancer. Genome Medicine. 3: 55. PMID 21875443 DOI: 10.1186/gm271 |
0.78 |
|
| 2011 |
Crighton J, Hall P, Lord S, Perrin T, Dodwell D. Surgical resection of isolated breast cancer recurrence within the sternum Bone. 48. DOI: 10.1016/J.Bone.2010.10.058 |
0.301 |
|
| 2010 |
Lord S, Harris AL. Angiogenesis - still a worthwhile target for breast cancer therapy? Breast Cancer Research : Bcr. 12: S19. PMID 21172081 DOI: 10.1186/bcr2748 |
0.536 |
|
| 2009 |
Lord SR, Vasudev N, Knight S, Speirs V, Hall G. Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e16551. PMID 27960814 DOI: 10.1200/jco.2009.27.15_suppl.e16551 |
0.318 |
|
| Show low-probability matches. |